Mackenzie joins the developer of therapeutics for colds, flu and allergy with a long record of executive board level management within the biotechnology and pharmaceutical industries at companies including Cambridge Genetics, Oxford Biomedica, Avidex (now Immunocore). He was most recently SVP for business development and corporate strategy at Medigene and ceo of Roji (London). In addition, MacKenzie was formerly a departmental head in vaccine r&d at Wellcome and a Wellcome lecturer in immunology at the University of London.
CMPT has received €1.5m convertible loan from Inventages Venture Capital to support continuing operations and the upcoming clinical trial of its lead product for the common cold. CMPT has been supported funding from London-based Inventages Venture Capital and New Zealand-based BioPacificVentures since 2005.
CMP Therapeutics appoints ceo
Receives loan to support clinical trial of lead product for common cold
You may also like
Research & Development
Weight loss drugs such as Ozempic may prevent stroke and reduce brain injury related complications
Three studies presented at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke and related brain injuries or reduce the risk of stroke altogether
Research & Development
Qureight analyses of Insilico Medicine’s Phase IIa rentosertib data support preliminary efficacy results and future trial expansion
Qureight’s deep-learning image biomarkers and clinical data analytics platform used to analyse enrolled idiopathic pulmonary fibrosis (IPF) patient data, supporting efficacy outcome and expansion to larger global patient studies